1. In this case-control cohort study, treatment with glatiramer acetate, interferon-beta, fingolimod, alemtuzumab, and natalizumab all led to reduced conversion to secondary progressive Multiple Sclerosis (MS) compared to no Disease-Modifying Treatment (DMT).
2. Treatment with fingolimod, alemtuzumab, and natalizumab had reduced conversion to secondary progressive MS compared to glatiramer acetate and interferon-beta.


https://www.2minutemedicine.com/dise...ple-sclerosis/